POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen

详细信息    查看全文

• 作者：Adam L. Cohen^a ; ^b ; ^{adam.cohen@hci.utah.edu} ; Rachel E. Factor^b ; ^c ; Kathi Mooney^b ; ^d ; Mohamed E. Salama^c ; Mark Wade^b ; Victoria Serpico^a ; ^e ; Emily Ostrander^b ; Edward Nelson^b ; ^e ; Jane Porretta^b ; ^e ; Cindy Matsen^b ; ^e ; Philip Bernard^b ; ^c ; Ken Boucher^a ; ^b ; Leigh Neumayer^e ; ¹
• 关键词：Tamoxifen ; Ki-67 antigen ; Neoadjuvant therapy ; Breast neoplasms
• 刊名：The Breast
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：31
• 期：Complete
• 页码：219-223
• 全文大小：587 K
• 卷排序：31

文摘

Seven days of tamoxifen produces Ki67 decreases similar to longer courses. Ki67 decreases by an average of 40% after 7 days of tamoxifen. 73% of women had decreased Ki67 after 7 days of tamoxifen. Seven days of preoperative tamoxifen is safe and tolerable.